University of Hertfordshire

From the same journal

By the same authors

Role of immunotherapy in early muscle invasive urothelial or bladder cancer

Research output: Contribution to journalArticlepeer-review

Standard

Role of immunotherapy in early muscle invasive urothelial or bladder cancer. / Chhaya, Saachi ; Watts, Isabella; Ng, Kenrick; Mustapha, Rami ; Powles, Thomas ; Sharma, Anand; Vasdev, Nikhil.

In: BJUI Compass, 26.06.2022.

Research output: Contribution to journalArticlepeer-review

Harvard

Chhaya, S, Watts, I, Ng, K, Mustapha, R, Powles, T, Sharma, A & Vasdev, N 2022, 'Role of immunotherapy in early muscle invasive urothelial or bladder cancer', BJUI Compass.

APA

Chhaya, S., Watts, I., Ng, K., Mustapha, R., Powles, T., Sharma, A., & Vasdev, N. (2022). Role of immunotherapy in early muscle invasive urothelial or bladder cancer. Manuscript submitted for publication.

Vancouver

Chhaya S, Watts I, Ng K, Mustapha R, Powles T, Sharma A et al. Role of immunotherapy in early muscle invasive urothelial or bladder cancer. BJUI Compass. 2022 Jun 26.

Author

Chhaya, Saachi ; Watts, Isabella ; Ng, Kenrick ; Mustapha, Rami ; Powles, Thomas ; Sharma, Anand ; Vasdev, Nikhil. / Role of immunotherapy in early muscle invasive urothelial or bladder cancer. In: BJUI Compass. 2022.

Bibtex

@article{236dac84d99d4be480c08ec167e67607,
title = "Role of immunotherapy in early muscle invasive urothelial or bladder cancer",
abstract = "Objective To describe and highlight the current use of immune checkpoint inhibitors (ICIs) in the muscle-invasive bladder cancer (MIBC) treatment landscape, particularly focusing on the perioperative setting. We provide a comprehensive review of key trials of the use of ICI in the perioperative setting, discussing trial outcomes and limitations and reviewing the role of biomarkers. BackgroundICIs have recently been integrated into the treatment algorithm for metastatic urothelial carcinoma. Over 30 published studies have investigated the role of these agents in the radical treatment of MIBC. Some studies have demonstrating conflicting results, affecting widespread adoption in clinical practice. MethodsWe performed a narrative overview of the literature from databases including; PubMed, MEDLINE, Embase, European society of Medical Oncology/American Society of Clinical Oncology Annual Proceedings and clinicaltrials.gov databases up until December 2021.DiscussionWe described the results of key trials in the neoadjuvant and adjuvant setting and some of the reasons for conflicting study results, and the implications for clinical practice. Relevant biomarkers in the field are discussed, alongside a brief overview of the immune microenvironment in bladder cancer. ConclusionPerioperative immunotherapy has shown promising efficacy with low toxicity in the neoadjuvant setting. The two large trials in the adjuvant setting have been contradictory. The efficacy of perioperative immunotherapy combined with favorable tolerability and better toxicity profile compared to chemotherapy, with the potential for biomarker driven patient selection, may lead to a change in future practice. There is, however, a lack of long-term survival and toxicity data for those treated with immunotherapy, and this needs to be developed further to demonstrate an added survival benefit by using immunotherapy. ",
author = "Saachi Chhaya and Isabella Watts and Kenrick Ng and Rami Mustapha and Thomas Powles and Anand Sharma and Nikhil Vasdev",
year = "2022",
month = jun,
day = "26",
language = "English",
journal = "BJUI Compass",
issn = "2688-4526",

}

RIS

TY - JOUR

T1 - Role of immunotherapy in early muscle invasive urothelial or bladder cancer

AU - Chhaya, Saachi

AU - Watts, Isabella

AU - Ng, Kenrick

AU - Mustapha, Rami

AU - Powles, Thomas

AU - Sharma, Anand

AU - Vasdev, Nikhil

PY - 2022/6/26

Y1 - 2022/6/26

N2 - Objective To describe and highlight the current use of immune checkpoint inhibitors (ICIs) in the muscle-invasive bladder cancer (MIBC) treatment landscape, particularly focusing on the perioperative setting. We provide a comprehensive review of key trials of the use of ICI in the perioperative setting, discussing trial outcomes and limitations and reviewing the role of biomarkers. BackgroundICIs have recently been integrated into the treatment algorithm for metastatic urothelial carcinoma. Over 30 published studies have investigated the role of these agents in the radical treatment of MIBC. Some studies have demonstrating conflicting results, affecting widespread adoption in clinical practice. MethodsWe performed a narrative overview of the literature from databases including; PubMed, MEDLINE, Embase, European society of Medical Oncology/American Society of Clinical Oncology Annual Proceedings and clinicaltrials.gov databases up until December 2021.DiscussionWe described the results of key trials in the neoadjuvant and adjuvant setting and some of the reasons for conflicting study results, and the implications for clinical practice. Relevant biomarkers in the field are discussed, alongside a brief overview of the immune microenvironment in bladder cancer. ConclusionPerioperative immunotherapy has shown promising efficacy with low toxicity in the neoadjuvant setting. The two large trials in the adjuvant setting have been contradictory. The efficacy of perioperative immunotherapy combined with favorable tolerability and better toxicity profile compared to chemotherapy, with the potential for biomarker driven patient selection, may lead to a change in future practice. There is, however, a lack of long-term survival and toxicity data for those treated with immunotherapy, and this needs to be developed further to demonstrate an added survival benefit by using immunotherapy.

AB - Objective To describe and highlight the current use of immune checkpoint inhibitors (ICIs) in the muscle-invasive bladder cancer (MIBC) treatment landscape, particularly focusing on the perioperative setting. We provide a comprehensive review of key trials of the use of ICI in the perioperative setting, discussing trial outcomes and limitations and reviewing the role of biomarkers. BackgroundICIs have recently been integrated into the treatment algorithm for metastatic urothelial carcinoma. Over 30 published studies have investigated the role of these agents in the radical treatment of MIBC. Some studies have demonstrating conflicting results, affecting widespread adoption in clinical practice. MethodsWe performed a narrative overview of the literature from databases including; PubMed, MEDLINE, Embase, European society of Medical Oncology/American Society of Clinical Oncology Annual Proceedings and clinicaltrials.gov databases up until December 2021.DiscussionWe described the results of key trials in the neoadjuvant and adjuvant setting and some of the reasons for conflicting study results, and the implications for clinical practice. Relevant biomarkers in the field are discussed, alongside a brief overview of the immune microenvironment in bladder cancer. ConclusionPerioperative immunotherapy has shown promising efficacy with low toxicity in the neoadjuvant setting. The two large trials in the adjuvant setting have been contradictory. The efficacy of perioperative immunotherapy combined with favorable tolerability and better toxicity profile compared to chemotherapy, with the potential for biomarker driven patient selection, may lead to a change in future practice. There is, however, a lack of long-term survival and toxicity data for those treated with immunotherapy, and this needs to be developed further to demonstrate an added survival benefit by using immunotherapy.

M3 - Article

JO - BJUI Compass

JF - BJUI Compass

SN - 2688-4526

ER -